Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

We report long-term follow-up from the RESONATE-2 phase 3 study of the once-daily Bruton's tyrosine kinase inhibitor ibrutinib, which is the only targeted therapy with significant progression-free survival (PFS) and overall survival (OS) benefit in multiple randomized chronic lymphocytic leukem...

Celý popis

Podrobná bibliografie

Vydáno v:	Blood advances Ročník 6; číslo 11; s. 3440 - 3450
Hlavní autoři:	Barr, Paul M., Owen, Carolyn, Robak, Tadeusz, Tedeschi, Alessandra, Bairey, Osnat, Burger, Jan A., Hillmen, Peter, Coutre, Steve E., Dearden, Claire, Grosicki, Sebastian, McCarthy, Helen, Li, Jian-Yong, Offner, Fritz, Moreno, Carol, Zhou, Cathy, Hsu, Emily, Szoke, Anita, Kipps, Thomas J., Ghia, Paolo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	United States Elsevier Inc 14.06.2022 American Society of Hematology
Témata:	Adenine - analogs & derivatives Chlorambucil - adverse effects Clinical Trials and Observations Follow-Up Studies Humans Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Leukemia, Lymphocytic, Chronic, B-Cell - genetics Piperidines Pyrazoles - adverse effects Pyrimidines - adverse effects Treatment Outcome
ISSN:	2473-9529, 2473-9537, 2473-9537
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!